Evaluation of GREM1 and THBS2 As Prognostic Markers in in Non-Small Cell Lung Cancer.

Yufang Bao,Ershuai Yan,Na Wang
DOI: https://doi.org/10.1007/s00432-023-04746-7
2023-01-01
Journal of Cancer Research and Clinical Oncology
Abstract:To analyze the correlation between bone morphogenetic protein (BMP) antagonist Gremlin 1 (GREM1), Thrombospondin-2 (THBS2) and immune cell infiltration in non-small cell lung cancer (NSCLC) and the related clinical significance. A total of 150 NSCLC patients admitted to our hospital during May 2019–January 2022 were picked. The expression of GREM1 and THBS2 and the infiltration of immune cells in tumor tissues were detected through immunohistochemistry (IHC). These objects were graded as GREM1-positive group (n = 97), GREM1-negative group (n = 53), THBS2-positive group (n = 102) and THBS2-negative group (n = 48) according to the expression of GREM1 and THBS2. The correlation between the expression of GREM1 and THBS2 with immune cell infiltration and clinicopathological indicators was analyzed. Kaplan–Meier survival analysis was adopted to analyze the relationship between the expression of GREM1 and THBS2 and the prognosis in NSCLC tissues. The overall progression-free survival (PFS) of the two groups were compared by log-rank test. The results of IHC showed that the positive expression rate of GREM1 was 64.67
What problem does this paper attempt to address?